Reported Severe Hypersensitivity Reactions after Intravenous Iron Administration in the European Economic Area (EEA) Before and After Implementation of Risk Minimization Measures

Drug Safety

Volumn 43, Issue 1, 2020, Pages 35-43

  Nathell, Lennart ^a   Gohlke, Annegret ^b   Wohlfeil, Stefan ^c  

^a Nathell Medical AB   (Sweden)

^b IQVIA   (United States)

^c NONE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

FERRIC CARBOXYMALTOSE; FERRIC GLUCONATE; FERUMOXYTOL; IRON DERIVATIVE; IRON DEXTRAN; IRON ISOMALTOSE; IRON SACCHARATE; FERRIC ION;

ADULT; ANAPHYLAXIS; ARTICLE; DISEASE SEVERITY; DRUG HYPERSENSITIVITY; DRUG SAFETY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PHARMACOEPIDEMIOLOGY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; ADOLESCENT; ADVERSE DRUG REACTION; DRUG SURVEILLANCE PROGRAM; EUROPE; EUROPEAN UNION; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; YOUNG ADULT;

ADOLESCENT; ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; DRUG HYPERSENSITIVITY; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; EUROPE; EUROPEAN UNION; FEMALE; FERRIC COMPOUNDS; FERRIC OXIDE, SACCHARATED; HUMANS; INFUSIONS, INTRAVENOUS; IRON COMPOUNDS; MIDDLE AGED; PHARMACOEPIDEMIOLOGY; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 85074439509     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.1007/s40264-019-00868-5     Document Type: Article

References (27)

1. Vos T, Abajobir AA, Abate KH, Abbafati C, Abbas KM, Abd-Allah F, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390:1211–59. 10.1016/S0140-6736(17)32154-2.
2. Cappellini MD, Comin-Colet J, de Francisco A, Dignass A, Doehner W, Lam CS, et al. Iron deficiency across chronic inflammatory conditions: international expert opinion on definition, diagnosis, and management. Am J Hematol. 2017;92:1068–78. 10.1002/ajh.24820.
3. WHO/CDC. Worldwide prevalence of anaemia 1993–2005: WHO Global Database on Anemia. Geneva: WHO; 2008.
4. Bhandari S, Pereira DIA, Chappell HF, Drakesmith H. Intravenous irons: from basic science to clinical practice. Pharmaceuticals (Basel). 2018. 10.3390/ph11030082.
5. EMA CHMP. Assessment report for: Iron containing intravenous (IV) medicinal products EMA/549569/2013. 2013. http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/IV_iron_31/WC500150771.pdf. Accessed 8 Aug 2018.
6. Hussain I, Bhoyroo J, Butcher A, Koch TA, He A, Bregman DB. Direct comparison of the safety and efficacy of ferric carboxymaltose versus iron dextran in patients with iron deficiency anemia. Anemia. 2013;2013:169107. 10.1155/2013/169107.
7. Kidney Disease: Improving Global Outcomes. KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int Suppl. 2012;2:280–335.
8. Johansson SGO, Bieber T, Dahl R, Friedmann PS, Lanier BQ, Lockey RF, et al. Revised nomenclature for allergy for global use: report of the Nomenclature Review Committee of the World Allergy Organization, October 2003. J Allergy Clin Immunol. 2004;113:832–6. 10.1016/j.jaci.2003.12.591.
9. Bailie GR, Horl WH, Verhoef J-J. Differences in spontaneously reported hypersensitivity and serious adverse events for intravenous iron preparations: comparison of Europe and North America. Arzneimittelforschung. 2011;61:267–75. 10.1055/s-0031-1296198.
10. encepp.eu. Intravenous Iron Postauthorisation Safety Study (PASS): evaluation of the risk of severe hypersensitivity reactions. 2018. http://www.encepp.eu/encepp/viewResource.htm?id=24010. Accessed 1 Oct 2018.
11. EMA CHMP. New recommendations to manage risk of allergic reactions with intravenous iron-containing medicines. 2013. https://www.ema.europa.eu/documents/referral/intravenous-iron-containing-medicinal-products-article-31-referral-new-recommendations-manage-risk_en.pdf. Accessed 25 Jan 2019.
12. EMA CHMP. Annex IV conditions to the marketing authorisations. 2013. https://www.ema.europa.eu/en/documents/referral/intravenous-iron-containing-medicinal-products-article-31-referral-annex-iv_en.pdf. Accessed 17 Sep 2019.
13. Wang C, Graham DJ, Kane RC, Xie D, Wernecke M, Levenson M, et al. Comparative risk of anaphylactic reactions associated with intravenous iron products. JAMA. 2015;314:2062–8. 10.1001/jama.2015.15572.
14. Bijwerkingen Centrum Lareb. Intravenous iron preparations and allergic reactions. 2015. https://databankws.lareb.nl/Downloads/Signals_2015_Intravenous_iron.pdf. Accessed 7 May 2018.
15. Bager P, Hvas CL, Dahlerup JF. Drug-specific hypophosphatemia and hypersensitivity reactions following different intravenous iron infusions. Br J Clin Pharmacol. 2017;83:1118–25. 10.1111/bcp.13189.
16. Mulder MB, van den Hoek, Hester L, Birnie E, van Tilburg, Antonie JP, Westerman EM. Comparison of hypersensitivity reactions of intravenous iron: iron isomaltoside-1000 (Monofer((R))) versus ferric carboxy-maltose (Ferinject((R))). A single center, cohort study. Br J Clin Pharmacol. 2019;85:385–92. 10.1111/bcp.13805.
17. WHO Press. Pharmaceuticals Newsletter. Geneva: WHO Press; 2017.
18. Ehlken B, Nathell L, Gohlke A, Bocuk D, Toussi M, Wohlfeil S. Evaluation of the reported rates of severe hypersensitivity reactions associated with ferric carboxymaltose and iron(III) isomaltoside 1000 in europe based on data from EudraVigilance and VigiBase™ between 2014 and 2017. Drug Saf. 2019;42:463–71. 10.1007/s40264-018-0769-5.
19. Theophile H, Laporte J-R, Moore N, Martin K-L, Begaud B. The case-population study design: an analysis of its application in pharmacovigilance. Drug Saf. 2011;34:861–8. 10.2165/11592140-000000000-00000.
20. European Medicines Agency. EudraVigilance system overview. https://www.ema.europa.eu/en/human-regulatory/research-development/pharmacovigilance/eudravigilance/eudravigilance-system-overview. Accessed 27 Nov 2018.
21. IQVIA Commercial GmbH & Co. OHG. acts 2018. 2019. https://www.iqvia.com/-/media/iqvia/pdfs/library/publications/acts-2018-32nd-edition.pdf?_=1566977658185. Accessed 28 Aug 2019.
22. Bailie GR, Clark JA, Lane CE, Lane PL. Hypersensitivity reactions and deaths associated with intravenous iron preparations. Nephrol Dial Transplant. 2005;20:1443–9. 10.1093/ndt/gfh820.
23. Benoist Bd. Worldwide prevalence of anaemia 1993–2005 of: WHO global database of anaemia. Geneva: World Health Organization; 2008.
24. Moulis G, Sommet A, Durrieu G, Bagheri H, Lapeyre-Mestre M, Montastruc J-L. Trends of reporting of ‘serious’ vs. ‘non-serious’ adverse drug reactions over time: a study in the French PharmacoVigilance Database. Br J Clin Pharmacol. 2012;74:201–4. 10.1111/j.1365-2125.2012.04185.x.
25. Hazell L, Shakir SAW. Under-reporting of adverse drug reactions: a systematic review. Drug Saf. 2006;29:385–96.
26. Arora A, Jalali RK, Vohora D. Relevance of the Weber effect in contemporary pharmacovigilance of oncology drugs. Ther Clin Risk Manag. 2017;13:1195–203. 10.2147/TCRM.S137144.
27. Hoffman KB, Dimbil M, Erdman CB, Tatonetti NP, Overstreet BM. The Weber effect and the United States Food and Drug Administration’s Adverse Event Reporting System (FAERS): analysis of sixty-two drugs approved from 2006 to 2010. Drug Saf. 2014;37:283–94. 10.1007/s40264-014-0150-2.